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Objectives: Thirty minutes of unprotected ischemia produced a jeopardized heart
that was treated with a blood cardioplegic solution containing the natural erythro-
cyte and protein buffers. Cardioplegic pH was changed to 7.7 (buffered) or 7.2
(nonbuffered), and this was tested alone and after pretreatment with Na-H
exchange blockade (cariporide) to define their protective effects.
Methods: Twenty-four Yorkshire-Duroc pigs (27-34.5 kg) underwent 30 minutes of
normothermic global ischemia, followed by 30 minutes of aortic clamping during
protection with buffered (n  12) or nonbuffered (n  12) glutamate-aspartate–
enriched blood cardioplegic solution. Twelve hearts (6 buffered and 6 nonbuffered)
were pretreated with intravenous cariporide (5 mg/kg) 15 minutes before ischemia.
Results: Severe and comparable left ventricle dysfunction followed buffered or
nonbuffered cardioplegia: Preload recruitable stroke work recovered to 56% 21%
and 45%  20% of baseline levels; creatine kinase MB, conjugated dienes, and
myeloperoxidase activity markedly increased; moderate myocardial edema oc-
curred; and endothelin-1 increased 2-fold more than baseline values. Cariporide
pretreatment caused a similar return of preload recruitable stroke work to 86% 
9% and 90%  6% after buffered or nonbuffered cardioplegia (P  .05 vs
nonpretreated groups), allowed only minor creatine kinase MB and conjugated
diene changes, and reduced endothelin-1 release 3-fold compared with hearts
without sodium-hydrogen exchange blockage.
Conclusions: The severe ischemia-reperfusion injury of 30 minutes of normother-
mic ischemia is not altered by an acidic or alkalotic pH cardioplegic solution.
Correction of damage is achieved by adding Na-H exchange blocker therapy
before treatment with buffered and nonbuffered solutions; thus, sodium-hydrogen
exchange inhibition plays a more vital role in recovery than pH management.
Acidosis follows ischemia and is conventionally the enemy of thesurgeon who normally introduces a buffer to offset the cardiacresults of H accumulation. Acidosis contributes to organ failureand death by slowing cell metabolism to delay enzyme reactionsand impairs contraction by inhibiting the calcium-binding site ontroponin-C.1 Intracellular proton accumulation triggers the 2 ma-
jor cellular buffer mechanisms to retain a normal pH: (1) the sodium-hydrogen
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exchange (NHE) that exchanges intracellular H for Na
and (2) the sodium-bicarbonate symporter that allows en-
trance of bicarbonate and sodium into the cell. Anaerobiosis
limits the energy-dependent Na-K pump, and sodium
overload is compensated by the Na/Ca transporter,
allowing calcium accumulation.
Reperfusion washes out the extracellular space to allow
the full action of these transporters, especially when buff-
ering causes rapid realkalinization. A promptly restored
physiologic pH enhances intracellular calcium overload,
contributing to rigor, hypercontracture, and death.2 New
approaches suggest that NHE system blockade will delay
rapid realkalinization during reperfusion and avoid hyper-
contracture.3,4 This direct proton inhibition of calcium-in-
duced hypercontraction has been known as the pH paradox.5
We studied whether pH was a central feature of protec-
tion against damage or was management interrelated with
NHE exchangers that interface pH with potential damage
from calcium entry. Our objectives were to define the fol-
lowing: (1) the effectiveness of buffering the cardioplegic
reperfusion in extremely jeopardized hearts, (2) the contri-
bution of preischemic NHE inhibition to the low and high
pH cardioplegic reperfusate, (3) the importance of car-
dioplegic reperfusate pH during the management of se-
verely injured jeopardized hearts compared with pH-inde-
pendent calcium management, and (4) the possible
interaction of pH management and NHE blockage on cor-
onary endothelial damage after severe normothermic isch-
emic injury.
Materials and Methods
All animals received humane care in compliance with the “Prin-
ciples of Laboratory Animal Care,” formulated by the Institute of
Laboratory Animal Resources, and the “Guide for the Care and
Use of Laboratory Animals” prepared by the Institute of Labora-
tory Animal Resources, National Research Council, and published
by the National Academy Press, revised 1996.
Twenty-four Yorkshire-Duroc pigs (27-34.5 kg) were premed-
icated (ketamine 15 mg/kg and diazepam 0.5 mg/kg intramuscu-
larly) and anesthetized (pentobarbital 30 mg/kg intravenously).
Support with a volume-controlled ventilator (Servo 900C, Sie-
mens-Elema, Solna, Sweden) was started after tracheostomy and
endotracheal intubation. The femoral artery and vein were cannu-
lated, and arterial blood gases were measured to keep PO2, PCO2,
and pH values within the normal range. A pulmonary artery
balloon-tipped catheter (model 132F5, Baxter Healthcare Corp,
Irvine, Calif) measured cardiac output (thermodilution technique)
before and after cardiopulmonary bypass (CPB).
After median sternotomy, an apical solid-state pressure trans-
ducer-tipped catheter (MPC-500, Millar Inc, Houston, Tex) mon-
itored left ventricular (LV) pressure. LV dimensions were mea-
sured with endocardially placed 2-mm ultrasonic microtransducer
crystals (Sonometrics, London, Ontario, Canada). Two pairs of
crystals were oriented across the minor and major axes. LV vol-
ume was assessed by an ellipsoid-based formula. Pressure-volume
loops were recorded digitally (Sonometrics Corporation, London,
Ontario, Canada).
After systemic heparinization (300 U/kg), extracorporeal cir-
culation was achieved using a 12F aortic cannula and a dual-lumen
29F venous right atrial cannula with a membrane oxygenator
(Affinity NT541, Medtronic, Inc, Minneapolis, Minn) and extra-
corporeal pump (Sarns, Ann Arbor, Mich). The circuit prime was
1000 mL Plasma-Lyte solution (Baxter Healthcare Corp, Deer-
field, Ill), 700 mL stored porcine packed blood, and calcium
chloride for normocalcemia (1.0-1.2 mmol/L). Oxygen tension
was kept at 300 mm Hg and aortic pressure was kept at 50 to 70
mm Hg by adjusting the flow to keep approximately 70% mixed
venous oxygen saturation at 35°C to 37°C. Potassium, calcium,
and pH were kept at normal levels. Aortic pressure was measured
during delivery of cardioplegic solution. The blood cardioplegic
solution was hyperkalemic (20 mg KCl/L), hypocalcemic (0.2
mEq/L Ca2), and enriched with glutamate and aspartate.6 The
coronary sinus was cannulated for blood sampling, and the LV was
vented.
Experimental Protocol
All pigs underwent 30 minutes of normothermic aortic clamping
before adding 30 more minutes of ischemia with cardioplegic
protection with amino acid–enriched blood cardioplegic solution,
including warm induction, cold maintenance, and a warm reper-
fusate. Pigs were divided into 4 groups.
Buffered cardioplegic reperfusion. In 6 pigs, reperfusion pH
was 7.7  0.06 during the added 30 minutes with use of 4:1 blood
cardioplegic solution at 200 mL/L during warm induction (2
minutes), cold maintenance (2 minutes), each 15 minutes, and
warm reperfusate (3 minutes) before unclamping.6
Nonbuffered cardioplegic reperfusion. In 6 pigs, reperfusion
pH was 7.2  0.1, because buffer (tromethamine) was not added
to the cardioplegic solution.
Cariporide and buffered cardioplegic reperfusion. In 6 pigs,
5 mg/kg HOE-642 was added to the extracorporeal circuit 15
minutes before normothermic ischemia (cariporide half-life in
swine is 30 minutes), and a pH 7.7 blood cardioplegic solution was
given during 30 added minutes of aortic clamping.
Cariporide and nonbuffered cardioplegic reperfusion. In 6
pigs, 5 mg/kg HOE-642 was added 15 minutes before normother-
mic ischemia. A pH 7.2 blood cardioplegia was used because
tromethamine was not added.
Measurements. CPB was continued 30 minutes after unclamp-
ing the aorta. Global LV function before and 30 minutes after CPB
was assessed by pressure-volume analysis. LV pressure and vol-
ume were recorded during transient inferior vena cava occlusions
to obtain a series of evenly declining pressure-volume loops.
Global stroke work and end-diastolic volume were calculated with
a video-graphics program (Sonometrics). Preload recruitable
stroke work (PRSW) for each series was identified as the relation
between stroke work and end-diastolic volume, and quantified by
a slope (MW) and x-intercept (LW). The slope (erg · cm3 · 103)
provides a reliable measure of intrinsic myocardial performance
independent of loading, geometry, and heart rate.7,8 Postbypass
LV performance was the percentage of recovery from prebypass
values.
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Coronary Sinus Blood Analysis
Samples were taken 5 minutes after initiating CBP (baseline) and
just before ending CPB (reperfusion), whereas the coronary flow
rate was controlled at 100 mL/min into the crossclamped aorta to
fix delivery.
Conjugated diene (CD) levels to mark oxidant-mediated lipid
peroxidation were determined spectrophotometrically after chlo-
roform-methanol 2:1 (vol/vol) extraction. Concentration was ex-
pressed as absorbance at a wavelength of 240 nm per 0.5 mL
plasma. Creatine kinase (CK) MB (units/liter) was determined by
an ultraviolet-spectrophotometric method (Sigma Chemical Co, St.
Louis, Mo). Nitric oxide (NO) (micromoles/liter) was determined
as its spontaneous oxidation products, nitrite and nitrate, which
were converted to NO and quantitated by a chemiluminescence
assay using a nitrogen oxides analyzer (DASIBI Environmental
Corp, model 2108, Glendale, Calif). Endothelin (ET)-1 (pico-
grams/milliliter) was determined after sample purification (Ethyl
C2 Amprep minicolumns, Amersham Pharmacia Biotech, Piscat-
away, NJ) by an enzyme immunometric assay (ACETM EIA kit,
Cayman Chemical Company, Ann Arbor, Mich).
Myocardial Biopsy
At the end of the experiment, pigs were killed by bolus injections
of pentobarbital 5 mg followed by 15 mL cold hyperkalemic blood
(KCl, 30 mEq/L). Transmural LV myocardium samples (0.5 g
from anterior free wall) were immediately frozen in liquid nitrogen
until analyzed for neutrophil-specific myeloperoxidase activity
(units/gram). Tissue water content was measured by weight loss
before and after incineration.
Statistical Analysis
Statistical analysis within and between groups was performed with
multiple analysis of variance followed by application of the Stu-
dent t test with Bonferroni’s correction for multiplicity. All data
are expressed as mean  SD.
Results
LV Performance
There was no operative mortality. Reperfusion with blood
cardioplegia, with or without buffering, allowed 56% 
21% and 45%  20% PRSW recovery (from 58.1  8.2 to
37.9 15.2, and from 51.6 7.5 to 23.3 10.9 erg · cm3
· 103), respectively (Figure 1). There was no difference in
recovery related to pH management. Conversely, NHE in-
hibition markedly improved recovery of PRSW to 86% 
9% and 90%  6% (from 56.1  7.0 to 48.7  10.3, and
from 55.6  6.9 to 49.8  7.1 erg · cm3 · 103) (P  .05
vs nonpretreated groups) with buffered and nonbuffered
cardioplegic reperfusates.
Myocardial Damage
CK-MB without cariporide pretreatment increased similarly
with buffered (72  15 U/L) and nonbuffered (69  16
U/L) reperfusates (Figure 2). Conversely, cariporide pre-
treatment similarly decreased CK-MB in buffered (42  4
U/L) and nonbuffered (30  5 U/L) cardioplegic reperfu-
sates (P  .05).
High CD levels occurred in the non-pretreated groups
(Figure 3) and in the buffered and nonbuffered cardioplegic
groups without cariporide. Conversely, cariporide pretreat-
ment similarly reduced CD values in buffered and nonbuf-
fered groups (1.31  0.11 and 1.19  0.09 A/mL, respec-
tively).
Figure 1. Recovery of preload recruitable stroke work, expressed as percentage of preischemic control values (*P
< .05 vs non-cariporide groups).
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Myeloperoxidase activity averaged 0.029  0.004 U/g
after unprotected ischemia and either buffered or nonbuf-
fered (0.030  0.004 U/g) blood cardioplegic reperfusion.
Cariporide pretreatment reduced myeloperoxidase activity
to 0.014 0.004 U/g and 0.013 0.002, without difference
between buffered and unbuffered reperfusion groups (P 
.05 pretreated vs nonpretreated groups).
Sixty minutes of CPB without ischemia slightly in-
creased water content from 79.5%  0.5% to 80.4% 
0.1%. Significant water gain followed unprotected isch-
emia and controlled cardioplegic reperfusion without ca-
riporide (81.5% and 81.6% in buffered and nonbuffered
cardioplegic reperfusion groups) (Figure 4). Cariporide
pretreatment reduced water content to 80.2% and 80.1%
in buffered and nonbuffered groups, respectively, levels
similar to those in management of nonischemic hearts
with blood cardioplegia.
Endothelial Response
A 2-fold increase in ET-1 (1.25  0.07 pg/mL) followed
buffered (2.05  0.38 pg/mL) and nonbuffered (1.98 
0.36 pg/mL) cardioplegic administration. Cariporide pre-
Figure 2. Levels of CK-MB in units per liter from coronary sinus plasma, at baseline and after 30 minutes of
reperfusion (*P < .05 vs non-cariporide groups).
Figure 3. Levels of conjugated dienes in coronary plasma expressed as absorbance (A) per 0.5 mL, at baseline and
after 30 minutes of reperfusion (*P < .05 vs non-cariporide groups).
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treatment decreased ET-1 in buffered and unbuffered
groups (1.18  0.10 and 1.13  0.06 pg/mL) to levels
comparable with controls without ischemia (P  .05 vs
noncariporide groups). Baseline NO levels showed major
variability between groups, with an F less than 0.05 that
limited subsequent statistical analysis.
Discussion
We studied ways to protect jeopardized hearts that must
undergo an added interval of aortic clamping for surgical
repair. Our results show that cardioplegic solution pH man-
agement during simulated surgical repair does not influence
contractile dysfunction and abnormal biochemical and en-
dothelial markers of structural damage. These effects con-
trast with the beneficial protection of alkalotic solutions
during cardioplegic arrest in nonjeopardized hearts.9,10 We
hypothesize a mechanism related to a time-dependent cal-
cium accumulation after severe unprotected ischemia that is
so profound that pH management during cardioplegic reper-
fusion plays only a marginal role in improving myocyte and
endothelial recovery.
Our data do not question the role of buffering in less
jeopardized hearts requiring cardioplegic protection. Buff-
ering remains a central surgical theme, because alkalotic
buffering during cardioplegic arrest slows the evolution of
acidosis and delays NHE activation. Repetitive cardioplegic
deliveries maintain arrest and prolong the interval before
ischemic calcium overload becomes a threat for contractile
dysfunction. This process differs from the deep acidosis
after prolonged unprotected ischemia (ie,30 minutes) that
more severely activates NHE and produces intracellular
sodium and calcium overload, myocardial edema, and cal-
cium-induced damage.2,3,11-13
In this jeopardized heart study, controlled alkalotic hy-
pocalcemic cardioplegic reperfusion limited sudden hyper-
contracture, cytoskeleton loss, and sarcolemmal disruption,
but allowed only partial recovery of function. We ascribe
the persistent dysfunction to NHE activation from ischemic-
induced acidosis resulting in calcium accumulation. The
NHE inhibition-related improvement was independent of
the pH of the blood cardioplegic reperfusate, because im-
provement followed either acidotic (pH 7.2) or alkalotic (pH
7.7) methods of pH management (ie, with buffered vs
nonbuffered solutions). These findings indicate the opera-
tive factor may be calcium loading during the ischemia-
reperfusion interval, but intramyocardial ionic measure-
ments were not performed to confirm this concept.
Potential mechanisms to limit calcium loading include
maintaining arrest during early reperfusion, pretreating with
NHE inhibition, and limiting calcium loading with specific
blockade of Ca2 at cellular membrane and sarcolemmal
reticulum levels. Only cardioplegia and NHE blockade were
Figure 4. Left ventricular anterior free wall myocardial water content expressed as percentage of weight, taken
at the end of the reperfusion period (*P < .05 vs non-cariporide groups).
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combined in our experiments. Cariporide administration
before ischemia may have prevented ischemic injury, as we
showed previously.14 Cariporide’s 30-minute half-life al-
lowed some supplementation of the cardioplegic solution,
because marked improvement extended the functional ben-
efits of these acid and alkaline solutions without cariporide.
A third alternative, not tested in this study, is that cardiople-
gic cariporide supplementation prevented reperfusion in-
jury. We recently found that reserving cariporide supple-
mentation to only controlled reperfusion15 mirrored the
preoperative finding in this study. Clearly, inhibition of Na
H exchange has a broad application, because cariporide
can act as both a pretreatment14 in jeopardized hearts (as an
intravenous cardioplegic solution component because of its
30-minute half-life in this report) and a direct cardioplegic
additive during controlled reperfusion.15
Although pH management with either alkalotic or aci-
dotic cardioplegic solutions did not retard ET-1 release
without cariporide, NHE blockage limited ET-1 release in
both the buffered and nonbuffered studies. The NO effects
were variable, but an endothelial benefit was indicated be-
cause NHE blockade reduced leukocyte vascular adherence.
Coronary vasoactivity was not assessed to confirm this
endothelial benefit.
Therapeutic Potential
The clinical role of cariporide in modifying ischemia-reper-
fusion damage is not yet established. Experimental pretreat-
ment with NHE blockers reduces infarct size,2,3 improves
recovery of LV dysfunction after infarction,3 reduces apo-
ptosis,16 preserves adenosine triphosphate,17 and reduces
arrhythmias.13 Unfortunately, initial clinical trials with ca-
riporide did not prevent death or myocardial infarction in
high-risk nonsurgical patients,18 but they showed some ben-
efit in heart surgery patients with jeopardized muscle.3
Comparisons of effectiveness were limited by the wide
spectrum of methods of intraoperative protection. This re-
port evaluates the importance of buffering during NHE
inhibition in a single but well-tested cardioplegic strategy.6
Buffering remains a central and therapeutic factor during
aortic clamping in jeopardized hearts, but the experimental
model plays an important role in defining the interaction be-
tween pH management and NHE inhibition. The absence of a
difference between high pH and low pH solutions in non-
cariporide studies should not lead to the conclusion that buff-
ering is not important. A nonbicarbonate buffer, such as Tris-
hydroxymethylaminomethane, can avoid subsequent carbon
dioxide production and sodium loading, consequences de-
scribed with the use of bicarbonate.4 The critical factor is not
related to pH per se, but to how breakdown of a bicarbonate
buffer can accentuate acidosis and stimulate resultant Na/H
exchange and subsequent calcium loading.
Study Limitations
This study did not include tissue pH or ion flux measure-
ments over time, because repetitive biopsy measurements of
Na, Ca2, or water content could have affected the clinical
variables measured. Water content was measured at the end
of reperfusion and may be closely related to Na load.
We studied a stunned myocardium model because global
LV function may improve if more than 30 minutes of
support is provided or inotropic interventions started. Thirty
minutes of normothermic ischemia initiated a critical lesion
that was almost completely avoided by cariporide pretreat-
ment. We did not add the extra 30 minutes of aortic clamp-
ing without cardioplegic protection because such treatment
is essential in jeopardized hearts needing repair. This “all or
nothing” effect with cardioplegia may hide differences be-
tween the buffered and unbuffered groups, because the
injury in the pretreated animals was minor. However, this
design limitation was offset in other recent experiments in
which cariporide was added only during controlled reper-
fusion and produced similar results.15
Conclusion
The use of acidic or alkalotic pH management during car-
dioplegic reperfusion does not change functional, biochemical,
or endothelial recovery in severely jeopardized hearts. The
prevention of calcium overload by NHE inhibition pretreat-
ment corrects myocardial dysfunction after normothermic
ischemia, and pH management of the cardioplegic solution
does not affect this benefit. The absence of a salutary effect of
adding a cardioplegic buffer should not exclude buffering of
the cardioplegic solution. The prevention of intracellular cal-
cium overload by NHE blockade may be a critical supplement
to the cardioplegic reperfusate for enhancing myocyte and
endothelial recovery in severely jeopardized hearts.
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